C
Cabio Biotech Wuhan Co Ltd
SSE:688089
Cabio Biotech Wuhan Co Ltd
SSE:688089
Price:
18.85
CNY
2.33%
Market Closed
Market Cap:
¥3.2B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
C
|
Cabio Biotech Wuhan Co Ltd
SSE:688089
|
CN |
|
JA Solar Technology Co Ltd
SZSE:002459
|
CN |
|
Oriental Aromatics Ltd
NSE:OAL
|
IN |
|
Haci Omer Sabanci Holding AS
IST:SAHOL.E
|
TR |
Income Statement
Earnings Waterfall
Cabio Biotech Wuhan Co Ltd
Cabio Biotech Wuhan Co Ltd
Income Statement
Cabio Biotech Wuhan Co Ltd
Cabio Biotech Wuhan Co Ltd
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
348
N/A
|
359
+3%
|
374
+4%
|
433
+16%
|
446
+3%
|
461
+3%
|
485
+5%
|
270
-44%
|
270
+0%
|
556
+106%
|
595
+7%
|
601
+1%
|
596
-1%
|
|
| Gross Profit | ||||||||||||||
| Cost of Revenue |
(182)
|
(200)
|
(216)
|
(253)
|
(270)
|
(280)
|
(297)
|
(159)
|
(167)
|
(326)
|
(329)
|
(322)
|
(305)
|
|
| Gross Profit |
166
N/A
|
159
-4%
|
158
0%
|
180
+14%
|
175
-3%
|
181
+3%
|
188
+4%
|
111
-41%
|
104
-7%
|
229
+121%
|
265
+16%
|
279
+5%
|
291
+4%
|
|
| Operating Income | ||||||||||||||
| Operating Expenses |
(75)
|
(76)
|
(85)
|
(109)
|
(144)
|
(155)
|
(157)
|
(46)
|
(45)
|
(109)
|
(122)
|
(115)
|
(118)
|
|
| Selling, General & Administrative |
(49)
|
(55)
|
(58)
|
(82)
|
(82)
|
(85)
|
(88)
|
(29)
|
(27)
|
(69)
|
(74)
|
(65)
|
(67)
|
|
| Research & Development |
(31)
|
(34)
|
(40)
|
(30)
|
(34)
|
(35)
|
(34)
|
(22)
|
(24)
|
(44)
|
(47)
|
(46)
|
(45)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(5)
|
0
|
0
|
0
|
0
|
0
|
(8)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
6
|
13
|
13
|
8
|
(28)
|
(34)
|
(34)
|
4
|
5
|
12
|
(2)
|
(4)
|
(5)
|
|
| Operating Income |
91
N/A
|
83
-9%
|
73
-12%
|
71
-3%
|
32
-55%
|
26
-18%
|
31
+20%
|
65
+108%
|
58
-10%
|
120
+107%
|
144
+19%
|
164
+14%
|
174
+6%
|
|
| Pre-Tax Income | ||||||||||||||
| Interest Income Expense |
11
|
18
|
23
|
13
|
11
|
8
|
(1)
|
3
|
2
|
6
|
8
|
7
|
5
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
(33)
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
0
|
(0)
|
0
|
(1)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
34
|
27
|
24
|
28
|
27
|
26
|
26
|
8
|
6
|
13
|
12
|
14
|
14
|
|
| Pre-Tax Income |
136
N/A
|
127
-7%
|
120
-6%
|
78
-35%
|
69
-12%
|
60
-13%
|
56
-7%
|
77
+37%
|
66
-14%
|
140
+111%
|
163
+17%
|
185
+13%
|
193
+4%
|
|
| Net Income | ||||||||||||||
| Tax Provision |
(18)
|
(19)
|
(17)
|
(17)
|
(16)
|
(14)
|
(12)
|
(10)
|
(9)
|
(20)
|
(23)
|
(25)
|
(27)
|
|
| Income from Continuing Operations |
118
|
108
|
102
|
62
|
53
|
46
|
43
|
67
|
57
|
120
|
141
|
160
|
166
|
|
| Income to Minority Interest |
(0)
|
3
|
3
|
3
|
2
|
3
|
4
|
2
|
2
|
4
|
4
|
4
|
4
|
|
| Net Income (Common) |
118
N/A
|
111
-6%
|
105
-5%
|
64
-39%
|
55
-14%
|
49
-11%
|
47
-5%
|
69
+47%
|
60
-14%
|
124
+108%
|
145
+17%
|
164
+13%
|
170
+3%
|
|
| EPS (Diluted) |
0.98
N/A
|
0.93
-5%
|
0.62
-33%
|
0.38
-39%
|
0.33
-13%
|
0.29
-12%
|
0.28
-3%
|
0.41
+46%
|
0.36
-12%
|
0.74
+106%
|
0.86
+16%
|
0.98
+14%
|
1.01
+3%
|
|
Switch to:
Switch to:
See Also
Discover More
